Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)

Crit Rev Oncol Hematol. 2011 Dec;80(3):393-410. doi: 10.1016/j.critrevonc.2011.01.012. Epub 2011 Mar 8.


The clinical application of the pure beta emitter (90)Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of (90)Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between (90)Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of (90)Y-therapies from the last decade and discusses new perspectives of therapeutic development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Carcinoma, Hepatocellular / therapy
  • Clinical Trials as Topic
  • Embolization, Therapeutic*
  • Humans
  • Liver Neoplasms / therapy
  • Lymphoma, Non-Hodgkin / radiotherapy
  • Neoplasms / therapy*
  • Neuroendocrine Tumors / radiotherapy
  • Radioimmunotherapy*
  • Receptors, Peptide / metabolism*
  • Treatment Outcome
  • Yttrium Radioisotopes / metabolism
  • Yttrium Radioisotopes / therapeutic use*


  • Antibodies, Monoclonal
  • Receptors, Peptide
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan